Ennead

Ennead Therapeutics is a pre-clinical stage biotechnology company focused on developing first-in-class small molecule therapeutics that target the DNA damage response (DDR) pathway. Founded on research from NYU Langone Health, the company aims to exploit specific vulnerabilities in cancer cells' ability to repair DNA, thereby enhancing the efficacy of existing treatments or providing new monotherapy options. Their approach focuses on novel targets within the DNA repair machinery that have been historically difficult to drug. The company is backed by Deerfield Management and operates within the New York City biotech ecosystem as part of the Cure innovation hub.